Neridronic acid for treating complex regional pain syndrome

1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising parenterally administering neridronic acid in an acid form or a salt form to a human being suffering from complex regional pain syndrome, wherein a total of no more than about 500 mg of the neridronic acid is administered in divided parenteral doses, and wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).

2. The method of claim 1 , wherein the neridronic acid is in a salt form.

3. The method of claim 1 , wherein the neridronic acid is in an acid form.

4. The method of claim 1 , wherein the neridronic acid is administered daily, weekly, monthly, every two or three months, once a year or twice a year to the human being.

5. The method of claim 1 , wherein each division of the divided parenteral doses contains about 10 mg to about 150 mg of the neridronic acid.

6. The method of claim 1 , wherein the neridronic acid is administered to the human being in 2 to 50 divided parenteral doses.

7. The method of claim 1 , wherein the CRPS is CRPS type I.

8. The method of claim 1 , wherein the CRPS is CRPS type II.

9. The method of claim 1 , wherein the human being has a pain intensity of at least 8 cm on the 10 cm VAS or at least 8 on the 0-10 NRS.

10. The method of claim 1 , wherein a total of about 200 mg to about 500 mg of the neridronic acid is administered parenterally to the human being.

11. The method of claim 1 , wherein a total of about 400 mg of the neridronic acid is administered parenterally to the human being.

12. The method of claim 1 , wherein a total of about 100 mg to about 200 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.

13. The method of claim 1 , wherein a total of about 250 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.

14. The method of claim 11 , wherein the neridronic acid is administered in 2 to 6 divided parenteral doses.

15. The method of claim 14 , wherein each division of the divided parenteral doses contains about 50 mg to about 100 mg of the neridronic acid.

16. The method of claim 14 , wherein each division of the divided parenteral doses contains about 62 mg to about 63 mg of the neridronic acid.

17. A method of treating allodynia associated with complex regional pain syndrome, comprising parenterally administering neridronic acid in a salt form or an acid form to a human being suffering from allodynia associated with complex regional pain syndrome, wherein a total of about 150 mg to about 500 mg of the neridronic acid is administered in divided parenteral doses, and wherein the human being has a pain intensity of at least 7 cm on the 10 cm visual analogue scale (VAS) or at least 7 on the 0-10 numerical rating scale (NRS).

18. The method of claim 17 , wherein a total of about 200 mg to about 500 mg of the neridronic acid is administered parenterally to the human being.

19. The method of claim 17 , wherein a total of about 400 mg of the neridronic acid is administered parenterally to the human being.

20. The method of claim 17 , wherein a total of about 100 mg to about 200 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.

21. The method of claim 17 , wherein a total of about 250 mg of the neridronic acid is administered parenterally to the human being within a period of about 1 month.

22. The method of claim 18 , wherein the neridronic acid is administered in 2 to 50 divided parenteral doses.

23. The method of claim 22 , wherein each division of the divided parenteral doses contains about 10 mg to about 150 mg of the neridronic acid.

24. The method of claim 22 , wherein each division of the divided parenteral doses contains about 62 mg to about 63 mg of the neridronic acid.

25. The method of claim 17 , wherein the complex regional pain syndrome is CRPS type I.

26. The method of claim 17 , wherein the complex regional pain syndrome is CRPS type II.

27. The method of claim 17 , wherein each division of the divided doses of the neridronic acid is administered daily.

28. The method of claim 17 , wherein each division of the divided doses of the neridronic acid is administered weekly.

29. The method of claim 17 , wherein each division of the divided doses of the neridronic acid is administered monthly.

30. The method of claim 17 , wherein the human being has a pain intensity of at least 8 cm on the 10 cm VAS or at least 8 on the 0-10 NRS.